After a phenomenal run in 2025, we are carrying that same precise execution right into the heart of Q2 2026. To ensure you’re getting firsthand access to our independent research and market sweeps, make sure to head over to the iOS App Store and download ChartSwipe, or visit powerhouse.substack.com to plug directly into our private network.
This morning, the scanners lit up with a fresh slate of analyst upgrades. We’ve sifted through the noise to find the fundamental catalysts driving these institutional moves, along with a critical update on one of our favorite micro-cap biotech plays.
Here is the breakdown of the tickers dominating today’s upgrade lists.
$CRDL FEATURED IN THE WALLSTVAULT.COM
1. Packaging Corp. of America ($PKG) – The Breakout Play
The standout upgrade this morning comes from Deutsche Bank, which lifted $PKG to a Buy rating and raised its price target significantly to $256.
- The Catalyst: Analyst Hillary Cacanando pointed out that $PKG is sitting at a massive positive inflection point.Their per-day shipment growth is currently significantly outpacing the broader market.
- The Fundamentals: The integration of their recently acquired Greif containerboard assets is exceeding initial expectations, providing a clear line of sight to a $60 million synergy target. When you combine accelerating demand with exceptional operational efficiency, you get a premium valuation.
- The Trade: Keep a close eye on volume today. With the stock trading around $218, Deutsche Bank’s target implies roughly 17% upside. This is a classic momentum setup for those trading industrial and materials strength.
2. Essex Property Trust ($ESS) – The Real Estate Recovery
Real estate is all about location, and the smart money is rotating back into the West Coast. Piper Sandler stepped in this morning to upgrade $ESS, pushing their price target to $308.
- The Catalyst: The firm explicitly cited an “accelerating Bay Area recovery” as the primary driver for the aggressive upgrade.
- The Fundamentals: This comes right on the heels of $ESS posting a massive Q1 beat, delivering core FFO of $4.06 per share and seeing same-property revenues jump 3.9% year-over-year in Northern California.
- The Trade: For those looking for yield and stability without sacrificing capital appreciation, $ESS is proving that high-quality properties in desirable tech-heavy markets are bouncing back hard.
3. Amazon ($AMZN) & The Trade Desk ($TTD) – The Tech Leaders
While $PKG and $ESS got the explicit morning target hikes, $AMZN and $TTD are also dominating the institutional watchlists today.
- $AMZN: Amazon was freshly added to the Zacks Strong Buy list today following last week’s blowout earnings. With AWS margins hitting all-time highs (38%) and top-tier analysts at JP Morgan raising their targets to $330, Amazon remains the foundational play for the AI infrastructure super-cycle.
- $TTD: The Trade Desk is seeing serious positioning ahead of its May 7 earnings report. Analysts are locked in on their CTV (Connected TV) growth and the rapid adoption of their Kokai AI platform. With the ongoing shift of ad spend from linear to digital, $TTD is the infrastructure play for the future of media.
Biotech Watchlist: Cardiol Therapeutics ($CRDL)
$CRDL FEATURED IN THE WALLSTVAULT.COM
We cannot talk about high-growth setups without returning to the micro-cap space. $CRDL remains a top priority on our research list this week.
- Smart Money Flow: The institutional footprint here is undeniable. According to Whale Wisdom, a major fund has been aggressively accumulating a heavy position. My rule of thumb remains simple: anytime smart money participates heavily in a stock under the $2 mark, it demands your attention.
- The Setup: The company continues to drop solid news regarding their MAVERIC Phase III clinical trials and remains highly active in advancing their pipeline. Biotech investing is inherently binary and carries extreme risk, but the current chart setup and volume accumulation suggest that the market is beginning to price in a favorable clinical outlook.
- The Outlook: Keep $CRDL on your immediate radar. We are looking for price action to hold key support levels as they approach their upcoming data readouts and earnings.
Stay disciplined, manage your risk, and let the charts do the talking.
Becoming a consistent trader is not easy.
Most fail.
At News On Wall Street we have a program.
Nothing is guaranteed but, we are opening the doors!
Text us at 844-722-9743.
LEGAL COMPLIANCE & DISCLOSURES
NOT FINANCIAL ADVICE – EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY All information provided by News On Wall Street (the “Publisher”) is strictly for educational and informational purposes only. Nothing contained herein constitutes, or is intended to constitute, investment advice, a recommendation to buy, sell, or hold any security, or a solicitation of any kind. The Publisher is not a registered investment adviser, broker-dealer, or financial planner with any regulatory agency. We do not provide personalized investment recommendations and have no fiduciary duty to any reader or subscriber.
You should consult with a qualified, licensed financial professional (such as a registered investment adviser or broker-dealer) who can assess your individual financial situation, risk tolerance, investment objectives, and tax consequences before making any investment decision. Investing in micro-cap biotechnology stocks like Cardiol Therapeutics ($CRDL) carries extreme risk, including the potential for total loss of principal. Biotech companies frequently experience total failure of clinical programs, regulatory rejection, massive dilution, delisting, or bankruptcy. Volatility can be extreme, with shares sometimes moving 50% or more in a single day on news events.
HIGH-RISK WARNING SPECIFIC TO BIOTECHNOLOGY INVESTING Biotechnology investing is inherently binary and speculative. Most clinical-stage companies never generate profits, never receive regulatory approval, and ultimately result in significant or total investor losses. Factors that could cause actual results to differ materially from any expectations expressed here include (but are not limited to): failure of Phase II or Phase III clinical trials (such as the ARCHER or MAVERIC trials referenced), delays or denial of FDA or other regulatory approvals, manufacturing issues, competition from larger pharmaceutical companies, intellectual property challenges, dilution from future financings, changes in healthcare policy, clinical safety concerns, adverse events, inability to secure additional funding, loss of key personnel, and general market or economic conditions. Past clinical data is not a guarantee of future success in larger trials or commercialization.
FORWARD-LOOKING STATEMENTS SAFE HARBOR This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “project,” “may,” “will,” “could,” “should,” “potential,” “intend,” “forecast,” “target,” or similar expressions.
All forward-looking statements are based on current expectations, estimates, projections, and assumptions that involve risks and uncertainties. These statements speak only as of the date they are made, and the Publisher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those expressed or implied due to the numerous risks outlined above and in Cardiol’s SEC filings (10-K, 10-Q, 8-K, etc.). Nothing in this report is a guarantee of future performance, clinical success, regulatory approval, commercialization, or stock price appreciation.
SEC RULE 17(b) DISCLOSURE (PAID PROMOTION / AWARENESS CAMPAIGN) News On Wall Street (the “Publisher”) has been compensated $100,000 in cash by Cardiol Therapeutics Inc. (“Cardiol” or the “Company”) for the creation, distribution, and ongoing awareness efforts related to this report and associated content. This compensation covers the period from April 7, 2026, through May 27, 2026. The payment was made directly by the Company (or its agents) to the Publisher and constitutes a material conflict of interest.
This entire communication is a paid advertisement / sponsored awareness campaign. The Publisher was compensated specifically to publish, publicize, and circulate information regarding Cardiol’s securities. Under Section 17(b) of the Securities Act of 1933, this disclosure is required. Investors must assume that the Publisher’s objectivity is influenced by this relationship. THIS IS NOT INDEPENDENT RESEARCH. It is commissioned, paid-for promotional material. The Publisher is not acting as an independent analyst and does not claim to provide unbiased or impartial analysis.
CONFLICT OF INTEREST DISCLOSURE The Publisher and/or its principals, affiliates, officers, directors, employees, family members, or other associated parties may currently hold, or may in the future purchase or sell, positions in Cardiol Therapeutics ($CRDL) or any other securities mentioned without prior or subsequent notice to readers. The Publisher may buy or sell shares at any time, including before, during, or after the distribution of this report. This creates an inherent conflict of interest.
INFORMATION SOURCES, ACCURACY, AND LIABILITY Information in this report is derived from public sources believed to be reliable (Company press releases, SEC filings, etc.). However, the Publisher makes no representation or warranty as to the accuracy, completeness, or timeliness of any information provided. To the fullest extent permitted by law, News On Wall Street, its officers, directors, and affiliates shall not be liable for any direct, indirect, or consequential damages arising out of the use of this report, including trading losses or loss of profits.
PERFORM YOUR OWN DUE DILIGENCE (DYOR) Always conduct your own thorough independent research. Review Cardiol’s latest SEC filings at www.sec.gov, consult multiple independent sources, and speak with your own financial and legal advisors before investing. Do not rely solely on any paid promotional material.
By continuing to read or act upon any information provided by News On Wall Street, you acknowledge that you have read, understood, and agreed to this full Legal Compliance & Disclosures section in its entirety.
